REGN2810

DRUG7 trials

Conditions

Advanced MalignanciesAdvanced Non-small Cell Lung CancerMelanomaMetastatic Squamous Cell Carcinoma NeckMetastatic Squamous Cell Carcinoma of HeadNon-small Cell Lung CancerProstate Cancer MetastaticRecurrent Squamous Cell Carcinoma of Head

Phase 1

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

WithdrawnNCT02520245

Regeneron PharmaceuticalsAdvanced Malignancies

Start: 2015-08-31End: 2023-11-30Updated: 2016-11-07

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

CompletedNCT03002376

Regeneron PharmaceuticalsMelanoma

Start: 2017-04-10End: 2020-03-19Updated: 2020-04-20

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

CompletedNCT03198130

Regeneron PharmaceuticalsMetastatic Squamous Cell Carcinoma Neck, Metastatic Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Head +1

Start: 2017-07-03End: 2020-02-21Updated: 2020-03-19

Phase 2

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Active, not recruitingNCT03951831

Mark SteinProstate Cancer Metastatic

Start: 2019-05-16End: 2028-04-30Updated: 2025-04-25

Phase 3

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

CompletedNCT03409614

Regeneron PharmaceuticalsNon-small Cell Lung Cancer

Start: 2018-03-06End: 2025-02-27Updated: 2025-03-13

Unknown Phase

An exploratory tumor biopsy-driven study to understand the relationship between biomarkers and indicators of clinical response in immunomodulatory treatment naïve unresectable stage III/IV melanoma patients receiving REGN2810 (anti-PD-1)

Active, not recruitingNL-OMON49259

Regeneron Pharmaceuticals, Inc.melanoma unresectable melanoma

Start: 2018-03-07Target: 8Updated: 2024-02-28

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active, not recruitingNCT06269133

Regeneron PharmaceuticalsAdvanced Non-small Cell Lung Cancer

Start: 2024-02-21End: 2027-06-23Target: 1000Updated: 2025-08-27

Cancers2026-03-12

Evaluating the safety and effectiveness of cemiplimab in combination with platinum-doublet chemotherapy by demographic characteristics in first-line treatment of advanced non-small cell lung cancer: An ongoing multi-database real world evidence study in US patients.

Journal of Clinical Oncology2025-05-28

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.

2024-05-138 citations

64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1

ESMO Open2024-03-01

75P Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation

Immuno-Oncology Technology2023-12-012 citations

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.

2023-11-0254 citations

Cemiplimab + Chemo Shows Clinical Benefit in Advanced NSCLC

Oncology Times2023-06-201 citations

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology2023-06-012 citations

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.

Journal of Clinical Oncology2023-06-011 citations

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.

2023-03-2965 citations

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.

2022-08-25216 citations

Abstract PO-046: Single-cell profiling of tumor evolution and complex immune infiltrate induced by ADT and PD-1 blockade in metastatic hormone-sensitive prostate cancer

Cancer Research2020-11-01

Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing.

Journal of Clinical Oncology2020-05-201 citations

A single-arm phase II study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology2020-02-19

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.

Journal of Clinical Oncology2019-03-105 citations

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

Journal of Clinical Oncology2018-05-205 citations